Analyse RxSight, Inc. (RXST) — Kairos Score 46/100

À propos de RxSight, Inc.

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Informations clés

🕴️ Activité des initiés (90 jours)

7 transactions — 0 achats et 3 ventes déclarés par les dirigeants de RxSight, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur RXST dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur RXST.

• RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says
• RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.